<DOC>
	<DOC>NCT01102452</DOC>
	<brief_summary>To evaluate the result of PPB-R-203-02 based noodle and commercially available wet noodle on blood glucose control in 24 patients with diabetes for 2 days.</brief_summary>
	<brief_title>A Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in Patients With Diabetes</brief_title>
	<detailed_description>The MiniMed Medtronic CGMS (continuous glucose monitoring system), the first model approved by FDA, was used for subcutaneous glucose monitoring. The CGMS continually measures the glucose concentration of the interstitial fluid every 10 seconds and then stores an average glucose value for each 5 minutes period, for a total of up to 288 measurements each day.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1. Diabetes mellitus patient. 2. Aged between 20 to 65 years old. 3. Informed consent form signed. 1. A recent history of drug or alcohol abuse. 2. Sensitivity to analogous product. 3. Serious cardiovascular disorders. 4. Participation in another clinical investigation study. 5. Ongoing influenza, autoimmune disease and other metabolic diseases. 6. Pregnant or lactating women. 7. Individuals are judged by the investigators or coinvestigator to be undesirable as subjects.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>